Ranbaxy inks MoU with Russia's Yaroslavl region

Drug firm Ranbaxy Laboratories today said it has signed a memorandum of understanding (MoU) with the government of Yaroslavl region in Russia for cooperation in the field of healthcare and medical science.

"We are delighted to explore potential opportunities in Yaroslavl to build and strengthen the local pharmaceutical industry," Ranbaxy MD Arun Sawhney said in a statement.

As per the MoU, both the parties will cooperate in development of healthcare system and new medical technologies in the Yaroslavl region.

This will include expansion of educational programmes for medical and pharmaceutical community, collaboration in the field of clinical trials as well as improvement of drug safety monitoring in medical practice, it added.

As a first step, Ranbaxy will evaluate collaborations with local academic and research centers in Yaroslavl region to broaden the scope of medical educational programmes for professional medical and pharmaceutical community.

It will also look at cooperation in the area of clinical trials, the company said

The Yaroslavl Region in Russia is establishing a pharmaceutical zone and encouraging pharmaceutical companies to set up manufacturing facilities and conduct clinical research.

Ranbaxy has been present in the Russian pharmaceutical market for around 20 years.